Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Quest Pharmatech Inc
V.QPT
Alternate Symbol(s):
QPTFF
Healthcare
Biotechnology
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy...
products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:QPT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Next
(94)
•••
G1945V
X
View Profile
View Bullboard History
Post by
G1945V
on Jun 02, 2024 8:40am
Canada NewsWire 2 days ago-updates on SEDAR
Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director Quest is also pleased to announce the
...more
(94)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Mar 19, 2024 6:18am
RE:RE:RE:RE:RE:Interesting
In addition to the above, I highly doubt Shenzhen Hepalink a 15% owner of QPT will let Canaribio run away with Oregovomab unchallenged if that is where their intentions lie. Hepalink, our poison pill,
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(94)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Mar 18, 2024 6:26pm
RE:RE:RE:RE:Interesting
Let the Clinical Trial play out. Canaribio is on the hook no matter what. Let's hope Phase 111 succeeds. If it doesn't, Oregovomab would be worthless. Madiyalakan the CEO of both QPT &
...more
(16)
•••
TrickyGame
X
View Profile
View Bullboard History
Comment by
TrickyGame
on Mar 18, 2024 5:53pm
RE:RE:RE:Interesting
With $300 million deal that was done wrong denying QPT the cash for their 45% interest in oregovomab and that same 45% interest in oregovomab's potential sales I'm sure QPT will be able to
...more
(30)
•••
ARIMA11
X
View Profile
View Bullboard History
Comment by
ARIMA11
on Mar 18, 2024 5:26pm
RE:RE:Interesting
Not sure if tQPT have the funds for a lenghty legal battle with Canaribio in court. QPT have little revenues. Hoping that Canaribio will eventually provide some money (cash) which would help. Frankly
...more
(16)
•••
TrickyGame
X
View Profile
View Bullboard History
Comment by
TrickyGame
on Mar 18, 2024 1:26pm
RE:Interesting
I believe QPT has said they are willing to go to court to protect thier 45% interest in oregovomab. At best they end up getting Carariabio bonds and shares as payment for theier interest in oregovomab
...more
(30)
•••
ARIMA11
X
View Profile
View Bullboard History
Comment by
ARIMA11
on Mar 17, 2024 10:28pm
RE:Interesting
https://www.hepalink.com/en/MedicineBusiness/index.aspx https://www.hepalink.com/OncoVent/en/oreg.html Worth keeping an eye on this...
(30)
•••
ARIMA11
X
View Profile
View Bullboard History
Post by
ARIMA11
on Mar 17, 2024 10:11pm
Interesting
https://canariabio.com/eng/rnd/pipeline.php Still alot of phase II ongoing. Also this in the last meaningful release. https://ceo.ca/@newswire/oregovomab-phase-iii-clinical-study-fails-futility The
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 30, 2024 5:01pm
New Press Release - Quest Receives Cash Dividend Payment from OncoQuest
EDMONTON, AB, Jan. 30, 2024 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received a cash dividend...
read article.
(30)
•••
ARIMA11
X
View Profile
View Bullboard History
Post by
ARIMA11
on Jan 24, 2024 8:13pm
Interesting
https://www.annalsofoncology.org/article/S0923-7534(19)32244-6/fulltext Conclusions Careful consideration should be given to the decision to terminate a study for futility, as futility
...more
(30)
•••
ARIMA11
X
View Profile
View Bullboard History
Comment by
ARIMA11
on Jan 24, 2024 8:07pm
RE:RE:RE:RE:RE:Why did the Study fail?
Again, 61% of the trades today involved Anonymous brokers (1) 24-Jan 0.02 95000 1 7 24-Jan 3:29:09 PM 0.02 10,000 1 7 24-Jan 3:28:54 PM 0.02 10,000 1 7 24-Jan 12:55:23 PM 0.025 29,000
...more
(30)
•••
ARIMA11
X
View Profile
View Bullboard History
Comment by
ARIMA11
on Jan 24, 2024 8:01pm
RE:RE:RE:RE:Why did the Study fail?
Yes. They should. However, this release is very contradictory. On one hand, it not good and on the other its hopeful. Details are very sparse. Question at this point is are: 1. What is the make up of
...more
(94)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 24, 2024 7:34pm
RE:RE:RE:Why did the Study fail?
Yes, that's my understanding. Management should put out a simple explanation. G1945V
(16)
•••
TrickyGame
X
View Profile
View Bullboard History
Comment by
TrickyGame
on Jan 24, 2024 6:12pm
RE:RE:Why did the Study fail?
So you are saying the "interim progression-free survival" part of the study will be discontinued but the "overall survival" part of the study will continue? So there is still a
...more
(94)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Jan 24, 2024 3:39pm
RE:Why did the Study fail?
I believe that the DSMB is only advising CAB to discontinue the clinical trial for interim "progression-free survival" in the study subjects due to the futility evaluation. But recommends
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden